PRMT5 and cancer: We have previously described the discovery of TNG908, a brain-penetrantclinical-stage compound that selectively targets MTAP-deleted cancer cells by binding to and inhibiting PRMT5 cooperativelywith MTA, which is present in elevated concentrations in MTAP-deleted cells.